title: Histologic response of high-grade nonmetastatic osteosarcoma of the extremity to chemotherapy,.
abstract: In 510 patients with osteosarcoma of the extremity treated at the authors' institute between March 1983 and June 1995 with different regimens of neoadjuvant chemotherapy, factors that influenced the histologic response were investigated. The rate of total necrosis was not related to the patients' gender, age, site, size of tumor, serum of alkaline phosphatase values, or route of cisplatin administration. The histologic response significantly and independently correlated with the number of drugs administered before surgery and with the histologic subtype of the tumor. According to the number of drugs used, the percentage of total necrosis was 31% for a four-drug regimen, 18% for a three-drug regimen, and only 1.5% for a two-drug regimen. According to the histologic type, the rates of total necrosis were 41% for telangiectatic tumors, 36% for fibroblastic tumors, 15% for osteoblastic tumors, and 3% for chondroblastic tumors. The authors concluded that in neoadjuvant therapy of osteosarcoma, the histologic response to preoperative treatment, which correlates with prognosis, depends on the effectiveness of the chemotherapy regimen and on some features intrinsically inherent to the tumor. These data should be considered when selecting the type of treatment (adjuvant or neoadjuvant) and the combinations of drugs to be used in preoperative treatment of patients with osteosarcoma.
authors.affiliation: Service of Chemotherapy, Istituto Ortopedico Rizzoli, Bologna, Italy.
authors.forename: G
authors.initials: G
authors.lastname: Bacci
authors.forename: S
authors.initials: S
authors.lastname: Ferrari
authors.forename: F
authors.initials: F
authors.lastname: Bertoni
authors.forename: P
authors.initials: P
authors.lastname: Picci
authors.forename: P
authors.initials: P
authors.lastname: Bacchini
authors.forename: A
authors.initials: A
authors.lastname: Longhi
authors.forename: D
authors.initials: D
authors.lastname: Donati
authors.forename: C
authors.initials: C
authors.lastname: Forni
authors.forename: L
authors.initials: L
authors.lastname: Campanacci
authors.forename: M
authors.initials: M
authors.lastname: Campanacci
mesh_terms: D000293:Adolescent; D000328:Adult; D000671:Amputation, Surgical / Q000379:methods; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D001859:Bone Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology* / Q000601:surgery; D002648:Child; D002675:Child, Preschool; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D004305:Dose-Response Relationship, Drug; D004317:Doxorubicin / Q000008:administration & dosage; D005121:Extremities; D005260:Female; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage; D016015:Logistic Models; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage; D015999:Multivariate Analysis; D010020:Osteonecrosis / Q000473:pathology*; D012516:Osteosarcoma / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology* / Q000601:surgery; D011300:Preoperative Care; D011379:Prognosis; D012189:Retrospective Studies; D012720:Severity of Illness Index; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D004317:Doxorubicin; D002945:Cisplatin; D007069:Ifosfamide; D008727:Methotrexate